(Q38156603)

29 August 2017

Risk of posttransplant lymphoproliferative disorder associated with use of belatacept (English)

1 reference

29 August 2017

Spencer T Martin

1

1 reference

29 August 2017

Jaclyn T Powell

series ordinal

2

1 reference

29 August 2017

Monank Patel

series ordinal

3

1 reference

29 August 2017

Demetra Tsapepas

series ordinal

4

1 reference

29 August 2017

1 November 2013

1 reference

American Journal of Health-System Pharmacy

29 August 2017

1 reference

29 August 2017

70

1 reference

29 August 2017

22

1 reference

29 August 2017

1977-1983

1 reference

The natural history of chronic allograft nephropathy

29 August 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

Relationship between CD8+ T-cell phenotype and function, Epstein-Barr virus load, and clinical outcome in pediatric renal transplant recipients: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

Lymphomas after solid organ transplantation: a collaborative transplant study report

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

Costimulation blockade with belatacept in renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

Five-year safety and efficacy of belatacept in renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

Summary of the US FDA approval of belatacept

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

Managing risk in developing transplant immunosuppressive agents: the new regulatory environment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

An update on risk evaluation and mitigation strategies in transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

Risk factors for the development of post-transplant lymphoproliferative disorder in a large animal model

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120770

31 March 2020

Identifiers

DOI

10.2146/AJHP120770

1 reference

29 August 2017

1 reference